Skip to main content
ScholarsBetaWeill Cornell Medicine

Publications

14 publications

Funding

1 grant

Active

1 grant
  • MPI
    ARLG Pneumonia Direct Pilot ("Study")
    National Institute of Allergy and Infectious Diseases · 2023–2026 · via Duke University
    UM1AI104681-11

Clinical research

8 studies

Active

1 study
  • PI
    An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis
    PHASE3 · Basilea Pharmaceutica, Ltd. · OPEN TO ACCRUAL (as of 2026)
    Candidemia; Candidiasis, Invasive
    NCT05421858
Completed & closed trials (7)
  • PI
    Phase III, Adjudicator-blinded, Randomised Study to Evaluate Efficacy and Safety of Treatment With Olorofim Versus Treatment With AmBisome® Followed by Standard of Care in Patients With Invasive Fungal Disease Caused by Aspergillus Species
    PHASE3 · F2G Ltd · IRB STUDY CLOSURE (as of 2025)
    Invasive Aspergillosis
    NCT05101187
  • PI
    Pneumonia Direct Pilot
    Duke University · IRB STUDY CLOSURE (as of 2025)
    Pneumonia, Bacterial; Ventilator Associated Pneumonia
    NCT06181669
  • PI
    Long-Term Follow-up of Study 32: an open-label single-arm Phase IIb study of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi in patients lacking suitable alternative treatment options (F901318/0032-LTFU)
    F2G Ltd · IRB STUDY CLOSURE (as of 2025)
  • PI
    A Pilot Study of Ceftolozane-Tazobactam in Conjunction With Rapid Molecular Diagnosis for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
    PHASE4 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)
    Pneumonia; Hematologic Malignancy; Pseudomonas Aeruginosa Infection; Bacteremia; Hematopoietic Stem Cell Transplant (HSCT)
    NCT04673175
  • PI
    Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
    PHASE2 · F2G Ltd · IRB STUDY CLOSURE (as of 2023)
    Invasive Fungal Infections
    NCT03583164
  • PI
    Treatment of a single patient infected with Mycobacterium haemophilum infection using Clofazimine (Lamprene)
    Novartis Pharmaceuticals Corporation · IRB STUDY CLOSURE (as of 2022)
  • PI
    Compassionate use of clofazimine
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2020)